https://www.statnews.com/2020/04/14/patents-public-health-tension-covid-19/

The Covid-19 pandemic, devastating as it is, is producing some triumphs of collaborative research and innovation, as everyone from the World Health Organization to national laboratories, pharmaceutical companies, and Facebook groups of engineers race to fight the virus. But lurking behind this remarkable work is a threat: Some individuals or companies may exploit patents to profiteer off the crisis and could slow these innovative efforts to a crawl.

In this time of crisis, lawmakers must be wary of patents and be flexible and proactive in using the many legal tools available to check their harmful use. (See link for article)

________________

**Comment**

Great reminder of an all important topic Lyme/MSIDS patients are all too aware of: conflicts of interests slowing or even stopping true scientific progress.

Recently, regarding COVID-19, I posted that the Chinese are trying to patent the anti-viral, Remdesivir:  https://madisonarealymesupportgroup.com/2020/04/17/live-video-chat-remdesivir-data-chicago-hospital-seeing-rapid-recoveries-patients-discharged-in-less-than-a-week/There is currently a clinical trial for Remdesivir in which they are finding:

rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week.

A similar effect was found in rhesus monkeys:  https://www.nih.gov/news-events/news-releases/antiviral-remdesivir-prevents-disease-progression-monkeys-covid-19

Regarding Lyme/MSIDS, microbiologist Tom Greer recently wrote an excellent letter outlining this problem of conflicts of interests and patents: https://madisonarealymesupportgroup.com/2020/04/19/letter-to-chronic-lyme-denialists-from-a-microbiologist/

A while back, I too wrote an article highlighting the problems with the faulty research that continues to be done – ignoring an entire LARGE subset of people who have remaining symptoms:  https://madisonarealymesupportgroup.com/2019/02/22/why-mainstream-lyme-msids-research-remains-in-the-dark-ages/  The authorities continue to fixate on the acute stage of the disease as well as insist upon having positive blood serology when research has proven Lyme tests relying upon antibodies to be worthless. They also insist that patients have the EM rash to enter studies, when research also shows many never get a rash.

For more on Lyme testing: https://madisonarealymesupportgroup.com/2018/10/12/direct-diagnostic-tests-for-lyme-the-closest-thing-to-an-apology-you-are-ever-going-to-get/

Excerpt:

The 1994 serodiagnostic testing guidelines predated a full understanding of key B. burgdorferi antigens and have a number of shortcomings. These serologic tests cannot distinguish active infection, past infection, or reinfection.

https://www.boston25news.com/news/cdc-reviewing-stunning-universal-testing-results-boston-homeless-shelter/ Video in Link

CDC reviewing ‘stunning’ universal testing results from Boston homeless shelter

The Centers for Disease Control and Prevention is now “actively looking into” results from universal COVID-19 testing at Pine Street Inn homeless shelter.

 

BOSTON — The Centers for Disease Control and Prevention is now “actively looking into” results from universal COVID-19 testing at Pine Street Inn homeless shelter.

The broad-scale testing took place at the shelter in Boston’s South End a week and a half ago because of a small cluster of cases there.

Of the 397 people tested, 146 people tested positive. Not a single one had any symptoms. (See link for article)

 

https://www.medpagetoday.com/infectiousdisease/covid19/86007?xid=nl_popmed_2020-

Co-Infections Uncovered in One-Fifth of COVID-19 Samples

— Testing for other respiratory illnesses may not rule out COVID-19 — and vice versa
A computer rendering of various micro organisms as seen under a microscope
Just because a patient tests positive for the COVID-19 coronavirus doesn’t mean that other pathogens aren’t at work too, researchers found.

In a small sample in Northern California, 20.7% of respiratory specimens positive for SARS-CoV-2, the virus that causes COVID-19, were also positive for one or more additional pathogens, reported James Quinn, MD, of Stanford University School of Medicine in Stanford, California, and colleagues, writing in a research letter in JAMA.

They noted early reports from China that suggested potential co-infection with other respiratory pathogens was “rare,” though CDC suggested testing for other respiratory pathogens in patients with suspected COVID-19, adding “evidence of another infection could aid the evaluation of patients with potential COVID-19 in the absence of widely available rapid testing for SARS-CoV-2.”

Quinn and colleagues examined 1,217 nasopharyngeal specimens from symptomatic patients reporting, for example, cough, fever, and shortness of breath, and found 9.5% were positive for SARS-CoV-2, with 24 of those testing positive for additional pathogens, such as influenza, respiratory syncytial virus, and non-SARS-CoV-2 Coronaviridae.

In addition, patients with co-infections did not differ significantly in age (mean age 47) versus those infected with SARS-CoV-2 only (mean age 51).

The most common co-infections were

  • rhinovirus/enterovirus (7%)
  • respiratory syncytial virus (5%)
  • non-SARS-CoV-2 Coronaviridae (4%)

“These results suggest higher rates of co-infection between SARS-CoV-2 and other respiratory pathogens than previously reported,” Quinn and colleagues wrote.

“The presence of a non-SARS-CoV-2 pathogen may not provide reassurance that a patient does not also have SARS-CoV-2.”

While they noted their results were limited to a single region in California, as well as their limited sample size, they concluded routine testing for non-SARS-CoV-2 respiratory pathogens “is unlikely to provide clinical benefit unless a positive result would change disease management” (for example, neuraminidase inhibitors for influenza patients) during this COVID-19 pandemic.

Disclosures:

The authors disclosed no conflicts of interest.

To The Chronic Lyme Denialists

By Tom Grier

I am not writing to champion “chronic-Lyme-disease” or the many charlatans that create imaginative cures for vague symptoms, I am here to point out a couple facts that are always missing from articles criticizing chronic Lyme disease.

First of all, from the very beginning when Lyme disease was first discovered to be caused by the spirochete Borrelia burgdorferi, the Medical-Experts based all of their conclusions on serology tests.

At that time the patents for the ELISA serology tests from the CDC were held by seven top level CDC administrators, a clear financial conflict of interest in my eyes when stated were mandated to use the CDC tests that lasted the full length of their PATENTs and only ended when their patents expired. Odd coincidence???

64357008_10217935576008450_2638357839671721984_n

All the serology tests for Lyme disease are based on B-31 lab strain of Borrelia burgdorferi we now have 19 Lyme disease Borrelia species and only Bb is detected with these tests. Also Borrelia myamotoi (a TBRF), which is found in the same tick as Lyme disease is transmitted in just 20 minutes. So the theory that Lyme disease can’t be transmitted within 36-48 hours (Yale Medical Report by Marc Voortman) is allowing an undetectable Tick-Borne-Relapsing-Fever to enter the patients and despite Lyme-like symptoms the patients will always test negative on a Lyme disease ELISA test.

The medical experts got many things wrong since 1982:

  • No transplacental transfer (Gary Wormser and E. Shapiro)
  • Is not intracellular (Alan Barbour) 
  • Lyme ELISA tests are 99 % accurate (CDC website) 
  • Erythema-migrans Lyme rash must be the size of a basketball or bigger (Dr. Johann Bakken 2016 IDSA President) 
  • No one dies of lyme disease
  • Two-Tiered testing is better than a single test
  • Many more inaccurate statements continue to be propagated by the Lyme disease experts of yesteryear. Graphic shows more:

72449110_10219003856434793_5779133325767606272_n

So to find the truth, our group and others turned to PATHOLOGY as the gold standard, and what we found warrants the need for an International Multi-Center Tax-Payer funded Brain Autopsy Study to detect all Borrelia species in the deaths of Chronic Lyme patients, MS patients and dementia brains.

All pseudo-science aside: Lyme patients deserve better science and better studies based on PATHOLOGY not SEROLOGY.
Do the Brain Pathology first, then make your conclusions.

Thomas Grier, Study Administrator
Dr. Paul Duray Pathology Fellowship (A volunteer organization)

218-216-5670 / donatebrain@gmail.com

tomgrier@gmail.com

 

 

 

 

https://www.lymedisease.org/roth-horowitz-covid19/

06 APR 2020
By  Dorothy Kupcha Leland
__________________________
For another Chronic Lyme patient who had COVID-19:

The first patient to speak is Representative Karen Whitsett who credits President Trump’s promotion of a malaria drug, hydroxychloroquine, with her recovery from coronavirus. Other COVID-19 survivors also speak after her at the White House. During their informal discussions, Rep. Whitsett, who had a severe case of  COVID-19, brought up her chronic Lyme disease as an underlying condition. Throughout the 41-minute meeting, President Trump highlighted how serious and devastating Lyme disease is, stating that it “can kill you.”

__________________________

Although the following patient DID NOT have COVID-19, her Lyme disease herxes made her think she might have had it.

Is it COVID-19 or a Lyme disease herx? One woman’s story.